MedTrace Logo

Crizanlizumab for Treating COVID-19 Vasculopathy

NCT04435184 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2021-11-09

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to test the efficacy and safety of crizanlizumab in patients hospitalized with COVID-19.

Conditions

Interventions

DRUG

Crizanlizumab

Crizanlizumab 5.0 mg/kg in 100 ml IV once.

OTHER

0.9% saline

0.9% saline 100 ml IV once.

Sponsors & Collaborators

Principal Investigators

  • Charles J Lowenstein, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-09
Primary Completion
2020-11-28
Completion
2021-01-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04435184 on ClinicalTrials.gov